Adenosine - AHFS 24:04.04.

24
Products Adenosine is available under the name Adenocard IV as a 3-mg/mL solution with sodium chloride 9 mg/mL in 2- and 4-mL disposable syringes for intravenous bolus injection. Adenosine is also available under the name Adenoscan as a 3-mg/mL solution with sodium chloride 9 mg/mL in 20- and 30-mL vials for intravenous infusion only.(1-1/06) pH Adenocard IV: from 4.5 to 7.5. Adenoscan: from 4.5 to 7.5.(1-1/06) Trade Name(s) Adenocard IV, Adenoscan Administration Adenosine injections are administered intravenously. Adenocard IV is given as a rapid bolus injection by the peripheral intravenous route directly into a vein or into an intravenous line close to the patient and is followed by a rapid sodium chloride 0.9% flush. Adenoscan is given by continuous peripheral intravenous infusion only.(1-1/06) Stability Intact containers of adenosine injections should be stored at controlled room temperature. They should not be refrigerated, because of possible crystal formation. If crystallization occurs, let the solution warm to room temperature to dissolve the crystals. The solution must be clear prior to administration.(1-1/06) (1-1/06) Adenosine 6 mcg/mL in sodium chloride 0.9% was packaged in 5-mL glass ampuls. Based on analysis of high-temperature-accelerated decomposition, it was projected that the drug solution would be stable for at least five years at 4 and 25 C.(2115) Adenosine 2 mg/mL in sodium chloride 0.9% was packaged in glass vials and stored for six months at temperatures ranging from 4 to 72 C. Analysis found no loss of adenosine in samples stored at 4, 22, and 37 C.(2277) Adenosine 80 mg/L and 330 mg/L in cardioplegia solutions having high (100 mmol/L) and low (30 mmol/L) concentrations of potassium was stored at 4 and 23 C. The solutions also contained THAM 12 mmol/L, magnesium sulfate 9 mmol/L, dextrose 250 mmol/L, and citrate-phosphate-dextroseadenine solution 20 mL/L. No adenosine loss occurred after 14 days of storage in either solution.(2402) Syringes Undiluted adenosine (Fujisawa) 3 mg/mL was packaged as 25 mL in 60-mL polypropylene syringes (Becton Dickinson) and sealed with polyolefin tip caps (Sherwood Medical). The syringes were stored at 25, 5, and -15 C. The solutions remained visually clear, and analysis showed no loss of adenosine in 7 days at 25 C, 14 days at 5 C, and 28 days at -15 C. The drug's stability in glass vials was essentially identical under the same conditions.(2114) Adenosine (Fujisawa) diluted to 0.75 mg/mL with several infusion solutions was packaged as 25 mL in 60-mL polypropylene syringes (Becton Dickinson) and sealed with polyolefin tip caps (Sherwood Medical). The syringes were stored at 25, 5, and -15 C. The solutions remained visually clear, and analysis showed no loss of adenosine in 14 days for dextrose 5% in lactated Ringer's and lactated Ringer's injection and 16 days for dextrose 5% and sodium chloride 0.9%.(2114) Compatibility Information Solution Compatibility Adenosine Solution Dextrose 5% in Ringer's injection, lactated Dextrose 5% Ringer's injection, lactated Sodium chloride 0.9%

Mfr Mfr Conc/L Remarks BAa FUJ 750 mg Visually compatible with no loss in 14 days at 25, 5, and -15 C a FUJ 750 mg Visually compatible with no loss in 16 BA days at 25, 5, and -15 C a BA FUJ 750 mg Visually compatible with no loss in 14 days at 25, 5, and -15 C BAa FUJ 750 mg Visually compatible with no loss in 16

Ref

C/I

2114 C 2114 C 2114 C 2114 C

days at 25, 5, and -15 C

a Tested in PVC containers.

Y-Site Injection Compatibility (1:1 Mixture) Adenosine Drug Mfr Conc Mfr Conc Remarks Ref C/I a 2374 C Abciximab LI FUJ 3 mg/mL Visually compatible for 12 hr at 23 C 36 mcg/mL
a Tested in PVC containers.

References For a list of references cited in the text of this monograph, search the monograph titled HID references.

2013, American Society of Health-System Pharmacists, Inc. All rights reserved. Author: LAWRENCE A. TRISSEL, F.A.S.H.P. Copyright: 2013, American Society of Health-System Pharmacists, Inc. All rights reserved. Database Title: STAT!Ref Online Electronic Medical Library ISBN: ISBN-10: 1-58528-378-9 ISBN-13: 978-1-58528-378-1 Publication City: Bethesda, MD Publication Year: 2012 Publisher: American Society of Health-System Pharmacists Title: Handbook on Injectable Drugs - 17th Ed. (2013) Date Posted: 5/16/2013 4:56:15 PM CST (UTC -06:00) Date Accessed: 1/23/2014 7:47:13 AM CST (UTC -06:00) Electronic Address: http://online.statref.com/Document.aspx?fxId=141&docId=7 Location In Title: HANDBOOK ON INJECTABLE DRUGS - 17th Ed. (2013) "A" Monographs Adenosine - AHFS 24:04.04.24